News
J&J launches second PhIII COVID-19 trial
Johnson & Johnson group Janssen has initiated a second Phase III study of its experimental COVID-19 vaccine.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Johnson & Johnson group Janssen has initiated a second Phase III study of its experimental COVID-19 vaccine.